Re: FDA disclosure policy on ANDA/351(k) trade secrets
I strongly disagree. There is no FDA requirement that all ANDA/351(k) applicants for a given branded drug use the same exact testing methods for ensuring sameness to the branded drug and batch-to-batch consistency. Nor is the FDA likely to spoon-feed a second or third applicant the testing methods used by the first successful applicant, as was done in the Lovenox case; indeed, doing so, might subject the FDA to a lawsuit by the successful applicant for illegal disclosure of proprietary technology (which is a separate legal issue from the H-W Safe Harbor per se).
The bottom line, IMO, is that the generic-Lovenox case was sui generis. From now on, the FDA will behave differently to avert destruction of the economic foundation of the generic-drug/FoB industry (#msg-84460897).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.